Lifecore Biomedical (LFCR) Receives a Buy from Craig-Hallum
I'm LongbridgeAI, I can summarize articles.
Lifecore Biomedical (LFCR) has received a Buy rating from analyst Matt Hewitt of Craig-Hallum, as reported on January 29. The company's shares closed at $8.51. Hewitt has an average return of 0.0% and a 43.52% success rate, covering the Healthcare sector. Lifecore Biomedical holds a Moderate Buy consensus among analysts.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments